妙佑医疗国际的丛状神经纤维瘤护理 来自妙佑医疗国际员工 打印 妙佑医疗国际的神经纤维瘤病专科门诊享誉世界,可为患有这种复杂状况的患者(包括丛状神经纤维瘤患者)提供协调护理。遗传科医生、成人与儿童神经科医生、神经肿瘤科医生、放射科医生和神经外科医生通力合作,准确提供您所需要的护理。治疗团队还包括遗传咨询师、眼科医生、骨外科医生、皮肤科医生、疼痛医学专家以及耳鼻喉专科医生。 妙佑医疗国际明尼苏达州罗切斯特院区也为丛状神经纤维瘤患儿提供家庭友好型儿童中心。 所有这些亚专科专家汇聚一处,专注于分析您的病情,这意味着您得到的不仅仅是一种意见。整个团队将共同讨论您的护理方案,协调安排各项约诊,而高度专业化的丛状神经纤维瘤专家将齐心协力为您制定最佳治疗方案。 在其他地方通常需要几个月时间才能完成的事项,在妙佑医疗国际一般几天就可以完成。 先进的诊断与治疗妙佑医疗国际的医生可以使用最先进影像学和诊断工具,妙佑医疗国际的科学家一直以来也都致力于开发患者护理的前沿技术。 妙佑医疗国际的专科医生采用全面的基因检测、影像学检查以及视力和听力评估来诊断丛状神经纤维瘤。妙佑医疗国际的专家还为丛状神经纤维瘤提供先进的治疗方案,包括专门的外科护理。 神经纤维瘤病专科门诊还设有遗传咨询师,可以帮助您做出适合自己和家人的决定。在做出治疗决定时,咨询师可以帮助您考虑风险、家庭目标以及伦理和宗教标准。 申请预约 Aug. 19, 2025 打印 Share on: FacebookTwitterWeChatWeChatCloseWeibo 显示参考文献 Plexiform neurofibroma. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/plexiform-neurofibroma. Accessed July 18, 2025. Korf BR. Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis. https://www.uptodate.com/contents/search. Accessed July 18, 2025. Yang X, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Child's Nervous System. 2022; doi:10.1007/s00381-022-05513-8. Adam MP, et al., eds. Neurofibromatosis. In: GeneReviews. University of Washington, Seattle; 1993-2025. https://www.ncbi.nlm.nih.gov/books/NBK1116/. Accessed July 21, 2025. Neurofibromatosis. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/neurofibromatosis. Accessed July 22, 2025. Copley-Merriman C, et al. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: A systematic literature review. Adolescent Health, Medicine and Therapeutics. 2021; doi:10.2147/AHMT.S303456. AskMayoExpert. Neurofibromatosis 1 management. Mayo Clinic; 2025. Bergqvist C, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet Journal of Rare Diseases. 2020; https://doi.org/10.1186/s13023-020-1310-3. de Blank PMK, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro‑Oncology. 2022; doi:10.1093/neuonc/noac165. Moertel CL et al. ReNeu: A pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025; doi:10.1200/JCO.24.01034. Gross AM et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: A phase 2 trial. Nature Medicine. 2025; doi:10.1038/s41591‑024‑03361‑4. Fisher MJ, et al. Management of neurofibromatosis type 1‑associated plexiform neurofibromas. Neuro‑Oncology. 2022; doi:10.1093/neuonc/noac146. Medical review (expert opinion). Mayo Clinic. Aug. 3, 2025. 丛状神经纤维瘤症状与病因诊断与治疗医生与科室在 Mayo Clinic 治疗 CON-20586344 疾病与状况 丛状神经纤维瘤